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Abstract
Background: Hermansky-Pudlak syndrome (HPS) is a disorder of lysosome-related organelle
biogenesis characterized by oculocutaneous albinism and prolonged bleeding. These clinical findings
reflect defects in the formation of melanosomes in melanocytes and dense bodies in platelets. HPS
type-3 (HPS-3) results from mutations in the HPS3 gene, which encodes a 1004 amino acid protein
of unknown function that contains a predicted clathrin-binding motif (LLDFE) at residues 172–176.
Results: Clathrin was co-immunoprecipitated by HPS3 antibodies from normal but not HPS3 null
melanocytes. Normal melanocytes expressing a GFP-HPS3 fusion protein demonstrated partial co-
localization of GFP-HPS3 with clathrin following a 20°C temperature block. GFP-HPS3 in which the
predicted clathrin-binding domain of HPS3 was mutated (GFP-HPS3-delCBD) did not co-localize
with clathrin under the same conditions. Immunoelectron microscopy of normal melanocytes
expressing GFP-HPS3 showed co-localization of GFP-HPS3 with clathrin, predominantly on small
vesicles in the perinuclear region. In contrast, GFP-HPS3-delCBD did not co-localize with clathrin
and exhibited a largely cytoplasmic distribution.
Conclusion: HPS3 associates with clathrin, predominantly on small clathrin-containing vesicles in
the perinuclear region. This association most likely occurs directly via a functional clathrin-binding
domain in HPS3. These results suggest a role for HPS3 and its protein complex, BLOC-2, in vesicle
formation and trafficking.
Background
Hermansky-Pudlak syndrome (HPS [MIM: 203300]) is an
autosomal recessive disorder of vesicle biogenesis result-
ing in the dysfunction of lysosome-related organelles such
as melanosomes and platelet dense bodies [1-4]. Affected
patients have oculocutaneous albinism presenting as con-
genital nystagmus, reduced visual acuity, and varying
degrees of hypopigmentation of the skin, hair, and irides
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[5-7]. In addition, a platelet storage pool deficiency, man-
ifesting as absence of platelet dense bodies, causes loss of
the secondary aggregation response [2,8,9]. Clinically,
this results in easy bruising and epistaxis in childhood,
prolonged bleeding during dental extractions and surger-
ies, and excessive menstrual and postpartum bleeding [9].
Some HPS patients also develop granulomatous colitis or
a fatal pulmonary fibrosis [9,10].
To date, seven genes have been identified as causes of
human HPS subtypes (HPS-1 through HPS-7), and other
genes identified in mouse models of HPS may also cause
HPS in humans [4,11]. Of the human subtypes, only HPS-
2 ([MIM: 603401]) results from mutations in a gene
(AP3B1) with a known function. AP3B1 codes for the β3A
subunit of adaptor complex-3 (AP-3), a coat protein that
is involved in sorting transmembrane proteins to lyso-
somes and lysosome-related organelles [12-15]. This rec-
ognized function of AP-3 supports the paradigm that all
types of HPS result from abnormal vesicle formation and/
or trafficking.
Each of the gene products of HPS1  ([MIM: 604982;
[16,17]]), HPS3 ([MIM: 606118; [18,19]]), HPS4 ([MIM:
606682; [20,21]]), HPS5 ([MIM: 607521; [22,23]]), HPS6
([MIM: 607522; [22]]), and HPS7 ([MIM: 607145; [24]])
is unique, although some HPS proteins interact with each
other in Biogenesis of Lysosome-related Organelles Com-
plexes or BLOCs [22,24-26]. The fact that these proteins
have no homology to any known proteins, to each other,
or to known functional domains makes them challenging
candidates to investigate using in vitro methods.
In an attempt to understand the function of HPS gene
products, we focused on HPS3, a unique protein with a
predicted clathrin-binding domain. HPS-3 patients, with
mutations in the HPS3 gene, have absent platelet dense
bodies, mild to moderate hypopigmentation of skin and
hair, iris transillumination, and patchy hypopigmenta-
tion of the fundus [19]. The mouse ortholog of human
HPS-3, cocoa, demonstrates similar features [27,28]. The
HPS3  gene was identified by homozygosity mapping
using HPS patients from a central Puerto Rican genetic
isolate [18]. HPS3 is located on chromosome 3q24 and
has 17 exons and a 3,015-bp open reading frame that
codes for a 1004-amino acid protein. The central Puerto
Rican founder mutation in HPS3  is a 3.9-kb deletion
encompassing exon 1 and its surrounding introns [18].
The central Puerto Rican HPS population is distinct from
the HPS isolate in northwest Puerto Rico, in which a
founder mutation in the HPS1 gene results in a severe
form of HPS [16]. Several non-Puerto Rican HPS3 muta-
tions, as well as an Ashkenazi Jewish founder mutation in
HPS3, have now been identified [19].
The human HPS3 protein contains a predicted clathrin-
binding motif (LLDFE) at residues 172–176 that con-
forms to the consensus sequence L(L, I)(D, E, N)(L, F)(D,
E). This consensus was determined by amino acid
sequence alignment of the clathrin-binding regions in the
beta subunits of adaptor proteins 1, 2, and 3 (β1, β2, β3A,
and β3B), arrestin 3, and amphiphysin I and II [29]. This
'clathrin box' is sufficient for binding to the amino termi-
nal domain of the clathrin heavy chain [29]. The struc-
tures of peptide complexes containing the clathrin-
terminal domain and the clathrin-binding motifs of β-
arrestin 2 and β3A have been determined by crystallogra-
phy [30]. Both of these peptides bind, via their clathrin
box motifs, to the same site in the clathrin heavy chain's
terminal domain, with nearly identical bound
conformations.
Clathrin is the main component of protein coats that
assist in the formation of vesicles budding from the trans-
Golgi network (TGN), plasma membrane, and endo-
somes. Several clathrin-associated proteins regulate the
assembly of clathrin triskelions, composed of three heavy
chains and three light chains, into the polyhedral cages
that provide structure to intracellular vesicles. Some of
these proteins and protein complexes are also involved in
sorting cargo into vesicles and directing their transport
within the cell [31,32].
HPS-2 disease results from deficiency of the clathrin bind-
ing protein β3A [12-15], supporting a possible role for
other HPS proteins in clathrin binding. Hence, we investi-
gated the clathrin binding function of the HPS3 protein in
melanocytes and fibroblasts.
Results
Several avenues of investigation were pursued to substan-
tiate the predicted clathrin-binding activity of HPS3.
These studies employed the techniques of immunoprecip-
itation, immunofluorescence, live cell imaging, and
immunoelectron microscopy.
Immunoprecipitation
Whole cell lysates prepared from normal melanocytes and
from HPS3 null melanocytes, i.e., cells from a patient
homozygous for the 3.9-kb HPS3 founder deletion [18],
exhibited approximately equal amounts of clathrin (Fig-
ure 1a, left panel). Each whole cell lysate was then immu-
noprecipitated with polyclonal HPS3 peptide antibodies.
Clathrin, detected by antibodies to its heavy chain, co-
immunoprecipitated with HPS3 in the normal lysates but
not in the HPS3 null lysates (Figure 1a, right panel). These
results were obtained using either of two different mono-
clonal anti-clathrin heavy chain antibodies.BMC Cell Biology 2005, 6:33 http://www.biomedcentral.com/1471-2121/6/33
Page 3 of 10
(page number not for citation purposes)
Association of HPS3 with clathrin Figure 1
Association of HPS3 with clathrin. (a) Immunoprecipitation of clathrin with HPS3 antibodies. Western blots of normal 
(NL) and HPS3-null (HPS3) melanocyte lysates treated with clathrin heavy chain antibodies. Equal amounts of clathrin were 
detected in both lysates [left panel]. The lysates were immunoprecipitated with HPS3 antibodies, electrophoresed, and immu-
noblotted using clathrin heavy chain antibodies. HPS3 antibodies immunoprecipitated clathrin only in the normal and not in the 
HPS3-null melanocyte lysates [right panel]. (b) Amino acid sequences of the predicted clathrin-binding domain (residues 172–
176 of human HPS3, shown in blue) in the human, mouse and rat HPS3 proteins, and the surrounding amino acid sequences. (c) 
Confocal immunofluorescence microscopy of representative normal melanocytes electroporated with GFP-HPS3 [A] and GFP-
HPS3-delCBD [B] (in green) and co-stained with antibodies to clathrin (in red). GFP-HPS3 partially co-localized with clathrin 
on small vesicles (arrowheads) [A], but GFP-HPS3-delCBD did not [B]. (Bar = 20 µm).
c
b
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NL HPS3
HPS3 IP lysate
NL HPS3
GFP-HPS3 GFP-HPS3-delCBD
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Human(GI: 19923642): ...NEEFSLLDFERSLIIHI...
Mouse(GI: 20532114): ...NEEFSILNFERSLIIHI...
Rat (GI: 34855511): ...NEEFSMLNFERSLIIHI...
Consensus: ...NEEFS+L+FERSLIIHI...
CBD
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Immunofluorescence
At residues 172–176, the HPS3 protein has a predicted
clathrin-binding motif (LLDFE) that is conserved in
mouse and rat (Figure 1b). Using site-directed
mutagenesis, a GFP-HPS3-delCBD construct was created
in which the clathrin-binding motif was converted to non-
conserved amino acids (AAAPG). The interaction of clath-
rin-binding proteins with clathrin is a transient phenom-
ena [31,33,34]. To maximize the likelihood of observing
the association of GFP-HPS3 with clathrin by immunoflu-
orescence, a 20°C temperature block was employed. Incu-
bation at 20°C for 2 h was used to block trafficking out of
the trans-Golgi [35,36] and followed by transfer to 37°C
for 5 min to release the temperature block and resume
normal trafficking. Normal melanocytes expressing wild-
type GFP-HPS3 or GFP-HPS3-delCBD, so treated, were
then fixed and stained with clathrin heavy chain antibod-
ies. Cells expressing GFP-HPS3 demonstrated partial co-
localization with clathrin on one to several small vesicles
in the perinuclear area (representative cell, Figure 1c[A]).
In a representative experiment, 9 of 11 GFP-HPS3 express-
ing melanocytes showed this co-localization. In contrast,
0 of 10 cells exhibited co-localization of GFP-HPS3-del-
CBD with clathrin (Figure 1c[B]; p < 0.001 by Chi-square
analysis).
Live cell imaging of HPS3 and acidic vesicles Figure 2
Live cell imaging of HPS3 and acidic vesicles. (a) Lysotracker Red stained acidic vesicle trafficking in live HPS3 null fibrob-
lasts expressing GFP-HPS3 [A] or GFP-HPS3-delCBD [B]. Cells were imaged on a 37°C warming stage following a 2 h incuba-
tion at 20°C. Lysotracker Red stained acidic vesicles and GFP-HPS3 transiently co-localized in the perinuclear area [A]. Inset 
shows the location of the time series shown in (b). GFP-HPS3-delCBD did not localize predominantly to the perinuclear area 
and showed no co-localization with Lysotracker Red [B]. (b) Time series showing co-trafficking of GFP-HPS3 and Lysotracker 
Red stained vesicles from the perinuclear area in HPS3 null fibroblasts. Note transient association of GFP-HPS3 with an acidic 
vesicle as it travels peripherally over a period of time (see [additional file 1]).
a
b
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Live cell imaging
Trafficking of acidic vesicles, stained with Lysotracker Red,
was followed in live HPS3 null fibroblasts expressing
either GFP-HPS3 (Figure 2a[A]) or GFP-HPS3-delCBD
(Figure 2a[B]). Following a 20°C temperature block and
transfer to 37°C, acidic vesicles and GFP-HPS3 clustered
together in the perinuclear area (Figure 2b[A]). GFP-HPS3
transiently interacted with acidic vesicles and, in some
cases (arrows, Figure 2b), emerged together with them
from the perinuclear area (Figure 2b and [Additional file
1]). In contrast, following a 20°C block and transfer to
37°C, GFP-HPS3-delCBD was predominantly localized in
a punctate pattern in the periphery of the cell; no associa-
tion of GFP-HPS3-delCBD with acidic vesicles was
observed (Figure 2a[B]).
Immunoelectron microscopy
Normal melanocytes were fixed approximately 9 h after
transfection with GFP-HPS3. Expression of the GFP-HPS3
fusion protein was low at this time, thus minimizing
aggregation and other artifacts that can occasionally be
observed in overexpressing cells. Normal melanocytes
transfected with GFP-HPS3-delCBD were fixed later
(approximately 24 h after transfection) because of the
very low levels of expression obtained with this construct.
No aggregates were observed in the GFP-HPS3-delCBD
transfected cells.
GFP-HPS3 localized predominantly to small (50–100
nm) vesicles in the Golgi region (57 of 111 (51%) anti-
GFP immunogold particles; Table 1) and the vast majority
of these particles (53 of 57 (93%)) co-localized with clath-
rin (Figure 3, arrowheads; Table 1). At high magnification,
GFP-HPS3 labeling was demonstrated on well-defined
clathrin-containing vesicles (Figure 3[B,D,E]). Some of
these small clathrin-containing vesicles were found near
larger endosomal structures (Figure 3[B,D]). GFP-HPS3
labeling was generally less abundant on large endosomal
structures than on small vesicles (23 of 111 (21%) of anti-
GFP immunogold particles found on endosomes) and
fewer of these particles co-localized with clathrin (15 of
23 (65%); Figure 3[B,D], Table 1).
In contrast, GFP-HPS3-delCBD expressing cells demon-
strated very few anti-GFP immunogold particles on small
vesicles in the Golgi region (8 of 110 (7%)) and these
were only rarely found in association with clathrin (1 of 8
(13%); Figure 4, Table 1). The majority of anti-GFP
immunogold particles localized to the cytoplasm of GFP-
HPS3-delCBD expressing cells (63 of 110 (57%)), com-
pared with only 7% (8 of 111) in GFP-HPS3 expressing
cells (Figures 3 and 4, Table 1). These differences were sta-
tistically significant by Chi square analysis (p < 0.001;
Table 1).
No appreciable GFP-HPS3 or GFP-HPS3-delCBD labeling
was observed on clearly identifiable Golgi stacks (Figure
3[A,C], Figure 4[D], Table 1). As expected, clathrin labe-
ling appeared much more abundant than GFP labeling in
GFP-HPS3 or GFP-HPS3-delCBD expressing melanocytes.
Similar amounts of GFP labeling per cell were detected in
GFP-HPS3 and GFP-HPS3-delCBD expressing cells and
no GFP labeling was observed in untransfected cells. Not
all clathrin-containing membranes were associated with
GFP-HPS3, but the majority of GFP-HPS3 appeared to be
associated with a clathrin-containing membrane.
Table 1: Quantitation of immunogold label in normal melanocytes transfected with GFP-HPS3 or GFP-HPS3-delCBD1
Gold Particles Clathrin Association
Intracellular compartment GFP-HPS3 GFP-HPS3-delCBD GFP-HPS3 GFP-HPS3-delCBD
Small vesicles in Golgi area 2,3 5 785 31
Golgi stacks 1100
Other small vesicles 15 16 9 3
Endosomal structures 3 23 17 15 1
Mitochondria 2200
Melanosomes 3200
Nucleus 2100
Cytoplasm 2 86 30 3
Total 3 111 110 77 8
1 Anti-GFP immunogold particles were counted in a total of 28 GFP-HPS3 and 25 GFP-HPS3-delCBD expressing cells
2 Difference in number of gold particles per compartment, for GFP-HPS3-delCBD compared with GFP-HPS3, is statistically significant by Chi square 
analysis (p < 0.001)
3 Difference in number of gold particles found in association with clathrin, for GFP-HPS3-delCBD compared with GFP-HPS3, is statistically 
significant by Chi square analysis (p < 0.001)BMC Cell Biology 2005, 6:33 http://www.biomedcentral.com/1471-2121/6/33
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Discussion
HPS3 is unusual among HPS proteins in that it contains a
predicted functional domain, i.e., a clathrin-binding
motif (LLDFE) (Figure 1b). In this report, we describe evi-
dence for the association of HPS3 with clathrin. We dem-
onstrated that clathrin co-immunoprecipitates with
endogenous HPS3 in normal melanocytes; no clathrin
was immunoprecipitated in the absence of HPS3, i.e., in
HPS3 null cells. The necessity of the clathrin-binding
domain in HPS3 is supported by the partial co-localiza-
tion of GFP-HPS3 with clathrin only when this domain is
present, as demonstrated by both fluorescence and immu-
noelectron microscopy studies. Furthermore, localization
and trafficking of GFP-HPS3 with acidic vesicles (labeled
with Lysotracker Red) depends upon an intact clathrin-
binding domain.
The presence of a conserved clathrin-binding motif in
HPS3, combined with the supportive data mentioned
above, indicates that HPS3 most likely binds clathrin
directly. We cannot, however, rule out the possibility that
HPS3 interacts indirectly with clathrin. Recent studies in
mouse [37] and human [38] have shown that HPS3 (cocoa
mouse) interacts with HPS5 (ruby-eye-2 mouse) and HPS6
(ruby-eye mouse) in the BLOC-2 complex. Hence, HPS3
may function as an essential component of a complex,
such as BLOC-2, in which another member binds clathrin.
This seems unlikely, however, since HPS5 and HPS6 have
no conserved clathrin-binding sequence motifs.
In our ultrastructural studies, GFP-HPS3 was found pri-
marily on small (50 to 100 nm) clathrin containing vesi-
cles in the perinuclear/Golgi region of normal
melanocytes. Mutation of the clathrin-binding domain of
HPS3 resulted in a largely cytoplasmic distribution of the
fusion protein, suggesting that the clathrin-binding
domain is necessary for the correct localization of HPS3
and that clathrin recruits HPS3 to small vesicles. Interest-
ingly, no GFP-HPS3 was seen on Golgi stacks or on vesi-
cles budding from the TGN, nor was it localized to large
endosomal structures or mature melanosomes. In
melanocytes from HPS3 deficient patients, DOPA histo-
chemistry (used to identify extra-melanosomal sites of
functional tyrosinase) detected 50 nm DOPA positive ves-
Immunoelectron micrographs demonstrating co-localization of GFP-HPS3 and clathrin Figure 3
Immunoelectron micrographs demonstrating co-localization of GFP-HPS3 and clathrin. Double-labeling of anti-
GFP (10-nm gold) and anti-clathrin (20-nm gold) [A, B], or the reverse labeled anti-clathrin (10-nm gold) and anti-GFP (15-nm 
gold) [C, D, E] in normal melanocytes electroporated with GFP-HPS3. Co-localization of the two labels was shown on small 
(50–100 nm) clathrin-containing vesicles (arrowheads) in the Golgi region [A and C]. Co-localization was observed on small 
clathrin-labeled vesicles (arrowheads) but not on neighboring large endosomal structures [B and D]. High magnification of a 
small clathrin containing vesicle labeled with GFP-HPS3 [E]. CM = Cell Membrane, G = Golgi area, E = Endosomal structure. 
Bar = 100 nmBMC Cell Biology 2005, 6:33 http://www.biomedcentral.com/1471-2121/6/33
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icles distributed throughout the cell [39]. This was in con-
trast to the situation in normal melanocytes, in which the
small DOPA-positive vesicles were restricted to the Golgi
region. A possible explanation is that HPS3 (and perhaps
BLOC-2 as a whole) interacts with the small DOPA-posi-
tive vesicles via its clathrin-binding domain, escorting
them from the Golgi region to premelanosomes for deliv-
ery of their contents. In such a scenario, additional spe-
cialized accessory factors (perhaps other HPS proteins or
BLOCs) would regulate vesicle targeting, budding and
fusion events, clathrin coat assembly and disassembly,
and interactions with the cytoskeleton.
Future investigations should pursue the function of
BLOC-2 with the recognition that one of its components,
HPS3, binds clathrin and may, therefore, bind to vesicles.
This understanding allows for hypotheses regarding the
roles of HPS5 and HPS6 in BLOC-2. Possible roles could
include such functions as binding designated cargo, regu-
lating conformational changes of the complex, or tether-
ing proteins or vesicles for interactions with the BLOC-2
complex as a whole.
Conclusion
HPS3 associates with clathrin, predominantly on small
clathrin-containing vesicles in the perinuclear region. This
association most likely occurs directly via a functional
clathrin-binding domain in HPS3 and is supported by
immunoprecipitation, immunofluorescence, live cell
imaging and immunoelectron microscopy data.
Immunoelectron micrographs demonstrating no co-localization of GFP-HPS3-delCBD and clathrin.   Figure 4
Immunoelectron micrographs demonstrating no co-localization of GFP-HPS3-delCBD and clathrin.   Double-
labeling of anti-clathrin (10-nm gold) and anti-GFP (15-nm gold) in normal  melanocytes electroporated with GFP-HPS3-del-
CBD [A-D].  GFP-HPS3-delCBD (arrowheads) was largely cytoplasmic and distributed throughout the entire cell, from the 
perinuclear/Golgi region [A,B,D] to the tips [C].  No co-localization of the two labels (GFP-HPS3-delCBD and clathrin) was 
observed.  N=Nucleus, G=Golgi, E=Endosomal structure, M=Melanosome.  Bar = 500 nmBMC Cell Biology 2005, 6:33 http://www.biomedcentral.com/1471-2121/6/33
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Methods
Patients and cells
Normal human primary epidermal melanocytes used for
immunoelectron microscopy were obtained from neona-
tal foreskin and established as described [40,41]. HPS-3
patient (HPS3 null) primary epidermal melanocytes and
primary fibroblast cultures were obtained from skin biop-
sies and cultured as previously described [14]. All other
normal human primary epidermal melanocytes were pur-
chased from Cascade Biologics (Portland, OR). The HPS-
3 patients were enrolled in a protocol approved by the
National Human Genome Research Institute Institutional
Review Board to study the clinical and molecular aspects
of HPS. Written informed consent was obtained from the
patient or the patient's parent.
Immunoprecipitation and western blotting
Normal and HPS3 null melanocytes cell pellets were
resuspended in PBS containing 1% NP-40 and protease
inhibitors (Roche Molecular Biochemicals, Indianapolis,
IN). The cell lysates were cleared by centrifugation and the
resulting supernatants were incubated with HPS3
polyclonal peptide antibody (developed in rabbit against
the peptide KMGDLDMHRNEMKSHS) followed by incu-
bation with protein A/G agarose beads (Oncogene
Research Products, San Diego, CA). The agarose beads
were washed, boiled in SDS-loading buffer and
centrifuged. The resulting supernatants were electro-
phoresed on 4–12% SDS-PAGE gels (Invitrogen,
Carlsbad, CA) and electro-blotted onto nitrocellulose
membranes (Schleicher and Schuell, Keene, NH). The
membranes were blocked and incubated with mouse
monoclonal anti-clathrin antibodies (1:1000) (BD Bio-
sciences Pharmingen (San Diego, CA) or Affinity BioRea-
gents (Golden, CO), followed by incubation with HRP-
conjugated anti-mouse IgG secondary antibodies
(1:3000; Amersham Biosciences, Piscataway, NJ). Results
were visualized with enhanced chemiluminescence (ECL
Western Blotting Detection Reagents, Amersham Bio-
sciences, Piscataway, NJ) and exposure to CL-XPosure film
(Pierce Biotechnology, Rockford, IL) according to the
manufacturer's instructions.
GFP-HPS3 plasmid constructs
The HPS3 coding sequence was amplified from normal
human cDNA [GenBank: NM_032383] with sequence
specific primers and subcloned into pEGFP-C1 (Clontech,
Palo Alto, CA). Site-directed mutagenesis to replace the
clathrin-binding motif (LLDFE) at residues 172–176 with
the non-conserved amino acids AAAPG was performed
with the QuikChange Site-Directed Mutagenesis Kit
(Stratagene, La Jolla, CA) according to the manufacturer's
recommendations, using the forward primer 5'-AATGAG-
GAATTCTCAGCAGCGGCCCCTGGACGTTCTTTAAT-
TATAC-3' and its reverse complement. All constructs were
verified by sequencing before use.
Transfections
All transfections were performed by electroporation in an
Amaxa nucleofector electroporator (Amaxa GmbH, Ger-
many). Electroporation of melanocytes was performed as
described [42]. Fibroblasts were electroporated using
Amaxa reagents and 3 µg of plasmid DNA with the U_23
nucleofector program.
Fluorescence microscopy
Approximately 16 h after transfection with either GFP-
HPS3 or GFP-HPS3-delCBD normal melanocytes were
incubated at 20°C for 2 h to block trafficking out of the
trans-Golgi [35,36]. Cells were transferred to 37°C for 5
min to release the temperature block and resume normal
trafficking then fixed in 3% paraformaldehyde. Melano-
cytes allowed to express GFP-HPS3 or GFP-HPS3-delCBD
for longer than 24 h demonstrated some GFP aggregates
and decreased viability. Slides were blocked in PBS con-
taining 0.1% saponin, 100 µM glycine, 0.1% BSA and 2%
donkey serum followed by incubation with mouse mon-
oclonal clathrin heavy chain antibodies (1:200 dilution;
BD Biosciences Pharmingen). The cells were washed and
incubated with donkey anti-mouse antibodies conjugated
to ALEXA-555 (Molecular Probes), washed again, and
mounted in VectaShield (Vector Laboratories, Burlin-
game, CA).
Live cell imaging was performed on HPS3 null fibroblasts
expressing either GFP-HPS3 or GFP-HPS3-delCBD
approximately 16 h after transfection. Cells were incu-
bated at 20°C for 2 h followed by a 10 min incubation
with the acidic vesicle dye Lysotracker Red (10 nM; Molec-
ular Probes). The cells were then placed in fresh, pre-
warmed culture media and imaged on a 37°C warming
stage. All cells were imaged with a Zeiss 510 META
confocal laser-scanning microscope (Carl Zeiss, Microim-
aging Inc., Germany) using a 488 Argon and a 543 HeNe
laser. Images were acquired using either a Plan Apochro-
mat 63X/1.4 oil DIC or a 100× Plan Apochromat 100X/
1.4 oil DIC objective.
Immunoelectron microscopy
Normal melanocytes were fixed approximately 9 h or 24
h after transfection in 2% paraformaldehyde with 0.2%
glutaraldehyde in PHEM buffer for 2 h. After embedding,
cutting, cryoprotection and snap-freezing of the pellet,
ultrathin cryosections were labeled with mouse mono-
clonal antibodies to clathrin (1:100) (BD Biosciences
Pharmingen). The mouse monoclonal antibodies were
indirectly labeled with 20-nm protein A-gold particles via
a rabbit anti-mouse IgG bridging antibody (1:200)
(DakoCytomation, Denmark). The second labeling wasBMC Cell Biology 2005, 6:33 http://www.biomedcentral.com/1471-2121/6/33
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performed with a rabbit polyclonal anti-GFP antibody
(1:1000) [43], followed by 10-nm protein A-gold incuba-
tion. To exclude co-labeling artifacts, ultrathin cryosec-
tions were labeled with primary antibodies as above, but
incubated with 10-nm protein A-gold in the first labeling
and 15-nm protein A-gold in the second labeling. The
grids were contrasted with uranyl acetate and imaged with
a Philips EM 410 electron microscope (Philips, Eind-
hoven, The Netherlands). Quantitation of anti-GFP
immunogold labeling of cellular compartments and its
association with clathrin (anti-clathrin immunogold labe-
ling) was performed on randomly selected cells expressing
either GFP-HPS3 (28 cells) or GFP-HPS3-delCBD (25
cells) [44].
List of abbreviations
HPS, Hermansky-Pudlak syndrome; BLOC, biogenesis of
lysosome-related organelles complexes; GFP, green fluo-
rescent protein; CBD, clathrin-binding domain; TGN,
trans-Golgi network; DOPA, dihydroxyphenylalanine;
PBS, phosphate buffered saline; BSA, bovine serum albu-
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